Evidence map›Paper›PMID 34479623›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.

Feng Qi, Wenxing Qin, Yao Zhang, Yongde Luo, Bing Niu, Quanlin An, Biwei Yang, Keqing Shi, Zhijie Yu, Junwei Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng Qi *Institute of Clinical Science, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, China.
Wenxing Qin *Department of Oncology, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China.
Yao Zhang *Laboratory for Cellular Biomechanics and Regenerative Medicine, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, 430074, Wuhan, Hubei, China.
Yongde LuoThe First Affiliated Hospital of Wenzhou Medical University, 325000, Wenzhou, Zhejiang, China.
Bing NiuSchool of Life Sciences, Shanghai University, 200444, Shanghai, China.
Quanlin AnInstitute of Clinical Science, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, China.
Biwei YangInstitute of Clinical Science, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, China.
Keqing ShiThe First Affiliated Hospital of Wenzhou Medical University, 325000, Wenzhou, Zhejiang, China.
Zhijie YuThe First Affiliated Hospital of Wenzhou Medical University, 325000, Wenzhou, Zhejiang, China.
Junwei ChenLaboratory for Cellular Biomechanics and Regenerative Medicine, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, 430074, Wuhan, Hubei, China. chenjunwei@hust.edu.cn.ORCID http://orcid.org/0000-0002-5785-0984
Xin CaoInstitute of Clinical Science, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, China. caox@fudan.edu.cn.ORCID http://orcid.org/0000-0003-1722-023X
Jinglin XiaInstitute of Clinical Science, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, China. xiajinglin@fudan.edu.cn.ORCID http://orcid.org/0000-0003-1566-3934

Funding

interdisziplinäres zentrum für klinische forschung, universitätsklinikum würzburg JCTD-2019-07national natural science foundation of china 81572395national natural science foundation of china 81772590natural science foundation of shanghai 20ZR1410400the open funding of key laboratory of diagnosis and treatment of severe hepato-pancreatic diseases of zhejiang province 2018E10008
6 · The paper itself

Abstract

backgroundRecurrent hepatocellular carcinoma (HCC) shows strong resistance to sorafenib, and the tumor-repopulating cells (TRCs) with cancer stem cell-like properties are considered a driver for its high recurrent rate and drug resistance.

methodsSuppression of TRCs may thus be an effective therapeutic strategy for treating this fatal disease. We evaluated the pharmacology and mechanism of sulfarotene, a new type of synthetic retinoid, on the cancer stem cell-like properties of HCC TRCs, and assessed its preclinical efficacy in models of HCC patient-derived xenografts (PDXs).

resultsSulfarotene selectively inhibited the growth of HCC TRCs in vitro and significantly deterred TRC-mediated tumor formation and lung metastasis in vivo without apparent toxicity, with an IC

conclusionsOur study identified sulfarotene as a selective inhibitor for the TRCs of HCC, which targets a novel RARα-SOS2-RAS signal nexus, shedding light on a new, promising strategy of target therapy for advanced liver cancer.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell Line, TumorDrug Resistance, NeoplasmHumansLiver NeoplasmsMiceRetinoidsSignal TransductionSon of Sevenless ProteinsSorafenibAntineoplastic AgentsRetinoidsSon of Sevenless ProteinsSorafenibSos2 protein, mouseHepatocellular carcinomaRetinoidSOS2SulfaroteneTumor-repopulating cells

Identifiers

PMID34479623
PMCPMC8418008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.